Stockreport

Cellectis: Approval of UCART123 Amendment in AML to Accelerate Clinical Development

Cellectis S.A. - American Depositary Shares  (CLLS) 
Last cellectis s.a. - american depositary shares earnings: 3/4 04:30 pm Check Earnings Report
US:NASDAQ Investor Relations: cellectis.com/en/investors
PDF Increase of current tested dose levels from 6.25x104/kg to 2.5x105/kg Treatment interval shortens between patients from 42 days to 28 days, [Read more]